Antidepressant Augmentation for Partial Response to Fluoxetine
Augmentation of an SSRI such as fluoxetine is recommended for major depressive disorder with an inadequate response, using an evidence-based augmentation agent selected by symptom profile and tolerability.[1][2]
Among medication choices supported by randomized evidence, bupropion-SR is a common antidepressant augmentation option for residual symptoms after SSRI nonresponse.[3][4]
Medication Selection Algorithm
Evidence-based augmentation options for persistent depressive symptoms despite adequate SSRI treatment include the following.[1][2]
- Bupropion-SR (antidepressant augmentation).[1][3]
- Mirtazapine (antidepressant augmentation option).[2][4]
- Lithium (mood-stabilizer augmentation option).[1][2]
- Second-generation antipsychotic augmentation (for example, aripiprazole or quetiapine).[1][2]
Augmentation with buspirone or thyroid hormone is not recommended routinely due to limited or inconsistent evidence.[2]
Combining antidepressants that increase serotonergic load (for example, adding another SSRI or SNRI) should be avoided as a default strategy because augmentation trials primarily support non-serotonergic or non-antidepressant augmentation approaches.[1][2]
Key Evidence Supporting This Recommendation
In the STAR*D trial (level 2), augmentation of SSRI treatment with sustained-release bupropion produced similar remission rates to buspirone (HRSD-17 remission 29.7% vs 30.1%).[3]
VA/DoD identifies common augmentation practice as the addition of bupropion-SR to SSRI therapy after inadequate response, citing increased remission without a corresponding increase in adverse events in the available evidence base.[1]
A CANMAT guideline review found that augmentation with agents such as aripiprazole, olanzapine, quetiapine, and risperidone had superior efficacy to placebo in treatment-resistant depression with small-to-medium effect sizes.[4]
Network meta-analysis data support that quetiapine and aripiprazole have relatively robust evidence as augmentation agents, with attention to safety and tolerability tradeoffs.[5]
Monotherapy vs Combination Therapy
For major depressive disorder that does not fully remit on an adequate SSRI course, augmentation or switching is recommended as next-step pharmacotherapy rather than indefinite continuation of the same SSRI dose alone.[1][2]
Combination strategies are recommended when the goal is to preserve partial response to the current SSRI while addressing residual symptoms.[1][2]
Important Clarifications and Nuances
Augmentation decisions should account for adverse-effect burden and comorbidity, because second-generation antipsychotic augmentation increases risks such as weight gain and sedation and requires baseline and ongoing monitoring.[1][2]
Lithium augmentation requires renal, thyroid, and serum level monitoring.[1][2]
Bipolar disorder risk should be assessed before adding or intensifying antidepressant therapy, because antidepressant monotherapy or intensification in bipolar disorder can precipitate mania or hypomania.[1][2]
Initiation Thresholds and Indications
Medication augmentation is indicated when there is an inadequate response to an adequate dose and duration of an antidepressant trial for the current episode, rather than after very brief or subtherapeutic exposure.[1][2]
Specialist referral or specialty-level treatment is recommended for treatment resistance after multiple unsuccessful strategies.[1][2]
Common Pitfalls to Avoid
Routine augmentation with agents lacking supportive evidence should be avoided, including augmentation with benzodiazepines for more than 2 weeks and augmentation with buspirone, carbamazepine, lamotrigine, or valproate due to insufficient evidence.[2]
Routine augmentation with thyroid hormone is discouraged due to inconsistent evidence of effectiveness.[2]
Target Outcomes of Therapy
The objective of augmentation is increased remission or response rates from residual depressive symptom burden while maintaining acceptable tolerability.[1][2]
In STAR*D, remission and response outcomes were measured using HRSD-17 and QIDS-SR-16 in the SSRI nonremission population undergoing augmentation strategies.[3]
Most Practical “Best Add-On” Choice to Fluoxetine
For residual symptoms after SSRI nonremission where an additional antidepressant strategy is desired, bupropion-SR is a preferred add-on option supported by randomized evidence in SSRI augmentation.[1][3]
For prominent SSRI adverse effects (such as sexual dysfunction or fatigue) or for targeting apathy and low energy, bupropion-SR augmentation is typically favored over adding another serotonergic antidepressant.[1][3]
For more clearly treatment-resistant depression or when antidepressant augmentation response is inadequate, second-generation antipsychotic augmentation (such as aripiprazole or quetiapine) or lithium augmentation are evidence-based escalation options with monitoring requirements.[1][2][4][5]